Log In
Print
BCIQ
Print
Print this Print this
 

ATX-MS-1467

  Manage Alerts
Collapse Summary General Information
Company Apitope International N.V.
DescriptionVaccine containing 4 synthetic peptides derived from human myelin basic protein
Molecular Target Major histocompatibility complex class I (MHC)
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Peptide vaccine
Latest Stage of DevelopmentPhase II
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat relapsing forms of multiple sclerosis (MS); Treat relapsing multiple sclerosis (MS); Treat secondary progressive multiple sclerosis (SPMS)
Regulatory Designation

Partner

Merck KGaA


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today